blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3790865

EP3790865 - PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORYT [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  31.03.2023
Database last updated on 26.07.2024
FormerGrant of patent is intended
Status updated on  05.07.2022
FormerRequest for examination was made
Status updated on  30.05.2022
FormerGrant of patent is intended
Status updated on  16.01.2022
FormerRequest for examination was made
Status updated on  12.02.2021
FormerThe international publication has been made
Status updated on  27.12.2019
Formerunknown
Status updated on  04.09.2019
Most recent event   Tooltip31.03.2023Application deemed to be withdrawnpublished on 03.05.2023  [2023/18]
Applicant(s)For all designated states
Janssen Pharmaceutica NV
Turnhoutseweg 30
2340 Beerse / BE
[2021/11]
Inventor(s)01 / MARTIN, Connor L.
3210 Merryfield Row
San Diego, California 92121 / US
02 / FENNEMA, Elizabeth G.
3210 Merryfield Row
San Diego, California 92121 / US
03 / KUMMER, David A.
3210 Merryfield Row
San Diego, California 92121 / US
04 / NISHIMURA, Rachel T.
3210 Merryfield Row
San Diego, California 92121 / US
05 / WOODS, Craig R.
3210 Merryfield Row
San Diego, California 92121 / US
06 / WOLIN, Ronald L.
3210 Merryfield Row
San Diego, California 92121 / US
07 / JONES, William M.
1400 McKean Road
Spring House, Pennsylvania 19477 / US
08 / FOURIE, Anne M.
3210 Merryfield Row
San Diego, California 92121 / US
09 / XUE, Xiaohua
3210 Merryfield Row
San Diego, California 92121 / US
10 / GOLDBERG, Steven
3210 Merryfield Row
San Diego, California 92121 / US
 [2021/11]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2021/11]Warner, James Alexander
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
Application number, filing date19759038.317.06.2019
[2021/11]
WO2019IB55043
Priority number, dateUS201862686308P18.06.2018         Original published format: US 201862686308 P
[2021/11]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019243999
Date:26.12.2019
Language:EN
[2019/52]
Type: A1 Application with search report 
No.:EP3790865
Date:17.03.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 26.12.2019 takes the place of the publication of the European patent application.
[2021/11]
Search report(s)International search report - published on:EP26.12.2019
ClassificationIPC:C07D231/14, C07D405/12, A61P29/00, A61K31/415
[2021/11]
CPC:
C07D231/14 (EP,US); A61P29/00 (EP); C07D401/12 (US);
C07D403/10 (US); C07D405/12 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/11]
TitleGerman:PHENYLSUBSTITUIERTE PYRAZOLE ALS MODULATOREN VON RORYT[2021/11]
English:PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORYT[2021/11]
French:PYRAZOLES SUBSTITUÉS PAR PHÉNYLE UTILISÉS EN TANT QUE MODULATEURS DE RORYT[2021/11]
Entry into regional phase11.12.2020National basic fee paid 
11.12.2020Designation fee(s) paid 
11.12.2020Examination fee paid 
Examination procedure11.12.2020Examination requested  [2021/11]
11.12.2020Date on which the examining division has become responsible
22.07.2021Amendment by applicant (claims and/or description)
17.01.2022Communication of intention to grant the patent
27.05.2022Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
06.07.2022Communication of intention to grant the patent
17.11.2022Application deemed to be withdrawn, date of legal effect  [2023/18]
08.12.2022Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time  [2023/18]
Fees paidRenewal fee
14.06.2021Renewal fee patent year 03
31.03.2022Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A]WO2012174362  (RES TRIANGLE INST [US], et al) [A] 1-28 * pages 1-4; tables 1-5 *;
 [A]WO2014023367  (PHENEX PHARMACEUTICALS AG [DE]) [A] 1-28 * pages 105-119; example - *;
 [AP]WO2018123918  (KAKEN PHARMA CO LTD [JP], et al) [AP] 1-28* example - *
by applicant   - KORN, T.E. BETTELLI et al., "IL-17 and Thl7 Cells", Annu Rev Immunol, (20090000), vol. 27, pages 485 - 517
    - KOLLS, J. K.A. LINDEN, "Interleukin-17 family members and inflammation", Immunity, (20040000), vol. 21, no. 4, doi:doi:10.1016/j.immuni.2004.08.018, pages 467 - 76, XP001205649

DOI:   http://dx.doi.org/10.1016/j.immuni.2004.08.018
    - STAMP, L. K.M. J. JAMES et al., "Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis", Immunol Cell Biol, (20040000), vol. 82, no. 1, doi:doi:10.1111/j.1440-1711.2004.01212.x, pages 1 - 9, XP009092747

DOI:   http://dx.doi.org/10.1111/j.1440-1711.2004.01212.x
    - DONG, C., "Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells", Nat Rev Immunol, (20060000), vol. 6, no. 4, pages 329 - 33
    - MCKENZIE, B. S.R. A. KASTELEIN et al., "Understanding the IL-23-IL-17 immune pathway", Trends Immunol, (20060000), vol. 27, no. 1, doi:doi:10.1016/j.it.2005.10.003, pages 17 - 23, XP028058535

DOI:   http://dx.doi.org/10.1016/j.it.2005.10.003
    - IVANOV, IIB. S. MCKENZIE et al., "The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells", Cell, (20060000), vol. 126, no. 6, doi:doi:10.1016/j.cell.2006.07.035, pages 1121 - 33, XP008091324

DOI:   http://dx.doi.org/10.1016/j.cell.2006.07.035
    - CUA, D. J.J. SHERLOCK et al., "Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain", Nature, (20030000), vol. 421, no. 6924, doi:doi:10.1038/nature01355, pages 744 - 8, XP002971969

DOI:   http://dx.doi.org/10.1038/nature01355
    - LANGRISH, C. L.Y. CHEN et al., "IL-23 drives a pathogenic T cell population that induces autoimmune inflammation", J Exp Med, (20050000), vol. 201, no. 2, doi:doi:10.1084/jem.20041257, pages 233 - 40, XP001206021

DOI:   http://dx.doi.org/10.1084/jem.20041257
    - YEN, D.J. CHEUNG et al., "IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6", J Clin Invest, (20060000), vol. 116, no. 5, doi:doi:10.1172/JCI21404, pages 1310 - 6, XP009127727

DOI:   http://dx.doi.org/10.1172/JCI21404
    - TONEL, G.C. CONRAD et al., "Cutting edge: A critical functional role for IL-23 in psoriasis", J Immunol, vol. 185, no. 10, doi:doi:10.4049/jimmunol.1001538, pages 5688 - 91, XP055203326

DOI:   http://dx.doi.org/10.4049/jimmunol.1001538
    - BEUREL, E.HARRINGTON, L. E.JOPE, R. S., "Inflammatory T helper 17 cells promote depression-like behavior in mice", Biol Psychiatry, (20130000), vol. 73, no. 7, doi:doi:10.1016/j.biopsych.2012.09.021, pages 622 - 30, XP028997121

DOI:   http://dx.doi.org/10.1016/j.biopsych.2012.09.021
    - CHEN, Y. et al., "Emerging tendency towards autoimmune process in major depressive patients: A novel insight from Thl7 cells", Psychiatry Research, (20110000), vol. 188, no. 2, pages 224 - 230
    - CHANG, M. R. et al., "Antiobesity Effect of a Small Molecule Repressor of RORy", Mol Pharmacol., (20150000), vol. 88, no. 1, pages 48 - 56
    - MEISSBURGER, B. et al., "Adipogenesis and insulin sensitivity in obesity are regulated by retinoid-related orphan receptor gamma", EMBO Mol Med., (20110000), vol. 3, no. 11, pages 637 - 651
    - BARCZYK, A.W. PIERZCHALA et al., "Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine", Respir Med, (20030000), vol. 97, no. 6, pages 726 - 33
    - FUJINO, S.A. ANDOH et al., "Increased expression of interleukin 17 in inflammatory bowel disease", Gut, (20030000), vol. 52, no. 1, pages 65 - 70
    - LOCK, C.G. HERMANS et al., "Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis", Nat Med, (20020000), vol. 8, no. 5, doi:doi:10.1038/nm0502-500, pages 500 - 8, XP002542559

DOI:   http://dx.doi.org/10.1038/nm0502-500
    - KRUEGER, J. G.S. FRETZIN et al., "IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis", J Allergy Clin Immunol, vol. 130, no. 1, pages 145 - 154 e9
    - GAZOULI, M.I. PACHOULA et al., "NOD2/CARD15, ATG16L1 and IL23R gene polymorphisms and childhood-onset of Crohn's disease", World J Gastroenterol, vol. 16, no. 14, pages 1753 - 8
    - NUNEZ, C.B. DEMA et al., "IL23R: a susceptibility locus for celiac disease and multiple sclerosis?", Genes Immun, (20080000), vol. 9, no. 4, pages 289 - 93
    - BOWES, J.A. BARTON, "The genetics of psoriatic arthritis: lessons from genome-wide association studies", Discov Med, vol. 10, no. 52, pages 177 - 83
    - KOCHI, Y.Y. OKADA et al., "A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility", Nat Genet, vol. 42, no. 6, doi:doi:10.1038/ng.583, pages 515 - 9, XP055019443

DOI:   http://dx.doi.org/10.1038/ng.583
    - GARBER K., "Psoriasis: from bed to bench and bac", Nat Biotech, (20110000), vol. 29, doi:doi:10.1038/nbt.1906, pages 563 - 566, XP055307288

DOI:   http://dx.doi.org/10.1038/nbt.1906
    - PAPP, K. A., "Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis", N Engl J Med, (20120000), vol. 366, no. 13, doi:doi:10.1056/NEJMoa1109017, pages 1181 - 9, XP002726554

DOI:   http://dx.doi.org/10.1056/NEJMoa1109017
    - LEONARDI, C.R. MATHESON et al., "Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis", N Engl J Med, vol. 366, no. 13, doi:doi:10.1056/NEJMoa1109997, pages 1190 - 9, XP002681513

DOI:   http://dx.doi.org/10.1056/NEJMoa1109997
    - HUEBER, W.PATEL, D.D.DRYJA, T.WRIGHT, A.M.KOROLEVA, I.BRUIN, G.ANTONI, C.DRAELOS, Z.GOLD, M.H.DUREZ, P., "Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis", Sci Transl Med, (20100000), vol. 2, page 5272
    - Pure & Appl. Chem., (19760000), vol. 45, pages 11 - 30
    - Angew. Chem. Int. Ed. Engl., (19820000), vol. 21, pages 567 - 583
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.